{"id":1035761,"date":"2012-06-07T19:17:45","date_gmt":"2012-06-07T19:17:45","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/reprocell-launches-alzheimers-disease-model-based-on-ips-derived-human-neuronal-cells.php"},"modified":"2024-08-17T15:49:50","modified_gmt":"2024-08-17T19:49:50","slug":"reprocell-launches-alzheimers-disease-model-based-on-ips-derived-human-neuronal-cells","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/human-genetic-engineering\/reprocell-launches-alzheimers-disease-model-based-on-ips-derived-human-neuronal-cells.php","title":{"rendered":"ReproCELL Launches Alzheimer&#39;s Disease Model Based on iPS-derived Human Neuronal Cells"},"content":{"rendered":"<p><p>      YOKOHAMA,      Japan, June 7, 2012 \/PRNewswire\/ --    <\/p>\n<p>      ReproCELL, Inc. (CEO:Chikafumi Yokoyama PhD) announces today      that the company will start commercializing human iPS-derived      neurons in which an Alzheimer's disease related gene has been      incorporated.    <\/p>\n<p>      ReproCELL's scientists have successfully incorporated a gene      related to Alzheimer's disease using homologous recombinant      genetic engineering technology into undifferentiated human      iPS cells and then differentiated them into neurons. In these      cells, it has been confirmed that amyloid beta 42 is      accumulated at higher levels compared to normal neurons. This      phenomena is similar to what is observed in neurons of      Alzheimer's patients. Accordingly, ReproCELL's scientists      believe the newly developed iPS cells can be useful for drug      screening to identify new therapeutic molecules to treat      Alzheimer's disease patients.    <\/p>\n<p>      The company will start marketing the cells on June      13th, 2012.    <\/p>\n<p>      Details of data of the cells will be announced at the      10th annual meeting of ISSCR (International Society for      Stem Cell Research) at Yokohama, Japan (June      13th-16th, 2012).    <\/p>\n<p>      ReproCELL is a world-leading pioneer in commercializing human      pluripotent      stem cells as an effective tool for drug discovery and      development. The company has successfully launched      iPS-derived cardiomyocytes for cardiac toxicity testing,      followed by the launch of iPS-derived dopaminergic neurons      and hepatocytes for efficacy and toxicity screening of drug      candidates.    <\/p>\n<p>      This is the fourth product of the company using iPS      technology and the first cellular disease model incorporating      a disease-related gene.    <\/p>\n<p>      Contact:       <a href=\"mailto:info_en@reprocell.com\">info_en@reprocell.com<\/a> Tel: 81-(0)45-475-3887      KDX Shin-Yokohama 381 bldg. 8F, 3-8-11 Shin-Yokohama,      Kohoku-ku,      Yokohama, Kanagawa 222-0033, Japan    <\/p>\n<\/p>\n<p>Read the original here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/reprocell-launches-alzheimers-disease-model-154900887.html;_ylt=A2KJNTtL_tBPz2YA2lr_wgt.\" title=\"ReproCELL Launches Alzheimer&#39;s Disease Model Based on iPS-derived Human Neuronal Cells\" rel=\"noopener\">ReproCELL Launches Alzheimer&#39;s Disease Model Based on iPS-derived Human Neuronal Cells<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> YOKOHAMA, Japan, June 7, 2012 \/PRNewswire\/ -- ReproCELL, Inc.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/human-genetic-engineering\/reprocell-launches-alzheimers-disease-model-based-on-ips-derived-human-neuronal-cells.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[388386],"tags":[],"class_list":["post-1035761","post","type-post","status-publish","format-standard","hentry","category-human-genetic-engineering"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1035761"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1035761"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1035761\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1035761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1035761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1035761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}